Graft-versus-host disease biomarkers: Omics and personalized medicine

Sophie Paczesny, Nisha Raiker, Sam Brooks, Christy Mumaw

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective form of tumor immunotherapy available to date and the frequency of transplants continues to increase worldwide. However, while allo-HSCT usually induces a beneficial graft-versus-leukemia effect, a major source of morbidity and mortality following allo-HSCT is graft-versus-host disease (GVHD). Currently available diagnostic and staging tools frequently fail to identify those at higher risk for GVHD morbidity, treatment unresponsiveness, and death. Furthermore, there are shortcomings in the risk stratification of patients before GVHD clinical signs develop. In parallel, recent years have been characterized by an explosive evolution of omics technologies, largely due to technological advancements in chemistry, engineering, and bioinformatics. Building on these opportunities, plasma biomarkers have been identified and validated as promising diagnostic and prognostic tools for acute GVHD. This review summarizes current information on the types of GVHD biomarkers, the omics tools used to identify them, the biomarkers currently validated as acute GVHD markers, and future recommendations for incorporating biomarkers into new grading algorithms for risk-stratifying patients and creating more personalized treatment courses. Future directions will include randomized evaluations of these biomarkers in multicenter prospective studies while extending on the need for biomarkers of chronic GVHD.

Original languageEnglish
Pages (from-to)275-292
Number of pages18
JournalInternational Journal of Hematology
Volume98
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Precision Medicine
Graft vs Host Disease
Biomarkers
Hematopoietic Stem Cell Transplantation
Morbidity
Transplants
Computational Biology
Immunotherapy
Multicenter Studies
Leukemia
Prospective Studies
Technology
Mortality
Therapeutics

Keywords

  • Biomarkers
  • Graft-versus-host disease (GVHD)
  • Hematopoietic stem cell transplantation (HSCT)
  • Proteomics

ASJC Scopus subject areas

  • Hematology

Cite this

Graft-versus-host disease biomarkers : Omics and personalized medicine. / Paczesny, Sophie; Raiker, Nisha; Brooks, Sam; Mumaw, Christy.

In: International Journal of Hematology, Vol. 98, No. 3, 09.2013, p. 275-292.

Research output: Contribution to journalArticle

Paczesny, Sophie ; Raiker, Nisha ; Brooks, Sam ; Mumaw, Christy. / Graft-versus-host disease biomarkers : Omics and personalized medicine. In: International Journal of Hematology. 2013 ; Vol. 98, No. 3. pp. 275-292.
@article{9b9202b4149c4b5fb56655f78a8ee5fb,
title = "Graft-versus-host disease biomarkers: Omics and personalized medicine",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective form of tumor immunotherapy available to date and the frequency of transplants continues to increase worldwide. However, while allo-HSCT usually induces a beneficial graft-versus-leukemia effect, a major source of morbidity and mortality following allo-HSCT is graft-versus-host disease (GVHD). Currently available diagnostic and staging tools frequently fail to identify those at higher risk for GVHD morbidity, treatment unresponsiveness, and death. Furthermore, there are shortcomings in the risk stratification of patients before GVHD clinical signs develop. In parallel, recent years have been characterized by an explosive evolution of omics technologies, largely due to technological advancements in chemistry, engineering, and bioinformatics. Building on these opportunities, plasma biomarkers have been identified and validated as promising diagnostic and prognostic tools for acute GVHD. This review summarizes current information on the types of GVHD biomarkers, the omics tools used to identify them, the biomarkers currently validated as acute GVHD markers, and future recommendations for incorporating biomarkers into new grading algorithms for risk-stratifying patients and creating more personalized treatment courses. Future directions will include randomized evaluations of these biomarkers in multicenter prospective studies while extending on the need for biomarkers of chronic GVHD.",
keywords = "Biomarkers, Graft-versus-host disease (GVHD), Hematopoietic stem cell transplantation (HSCT), Proteomics",
author = "Sophie Paczesny and Nisha Raiker and Sam Brooks and Christy Mumaw",
year = "2013",
month = "9",
doi = "10.1007/s12185-013-1406-9",
language = "English",
volume = "98",
pages = "275--292",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Graft-versus-host disease biomarkers

T2 - Omics and personalized medicine

AU - Paczesny, Sophie

AU - Raiker, Nisha

AU - Brooks, Sam

AU - Mumaw, Christy

PY - 2013/9

Y1 - 2013/9

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective form of tumor immunotherapy available to date and the frequency of transplants continues to increase worldwide. However, while allo-HSCT usually induces a beneficial graft-versus-leukemia effect, a major source of morbidity and mortality following allo-HSCT is graft-versus-host disease (GVHD). Currently available diagnostic and staging tools frequently fail to identify those at higher risk for GVHD morbidity, treatment unresponsiveness, and death. Furthermore, there are shortcomings in the risk stratification of patients before GVHD clinical signs develop. In parallel, recent years have been characterized by an explosive evolution of omics technologies, largely due to technological advancements in chemistry, engineering, and bioinformatics. Building on these opportunities, plasma biomarkers have been identified and validated as promising diagnostic and prognostic tools for acute GVHD. This review summarizes current information on the types of GVHD biomarkers, the omics tools used to identify them, the biomarkers currently validated as acute GVHD markers, and future recommendations for incorporating biomarkers into new grading algorithms for risk-stratifying patients and creating more personalized treatment courses. Future directions will include randomized evaluations of these biomarkers in multicenter prospective studies while extending on the need for biomarkers of chronic GVHD.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective form of tumor immunotherapy available to date and the frequency of transplants continues to increase worldwide. However, while allo-HSCT usually induces a beneficial graft-versus-leukemia effect, a major source of morbidity and mortality following allo-HSCT is graft-versus-host disease (GVHD). Currently available diagnostic and staging tools frequently fail to identify those at higher risk for GVHD morbidity, treatment unresponsiveness, and death. Furthermore, there are shortcomings in the risk stratification of patients before GVHD clinical signs develop. In parallel, recent years have been characterized by an explosive evolution of omics technologies, largely due to technological advancements in chemistry, engineering, and bioinformatics. Building on these opportunities, plasma biomarkers have been identified and validated as promising diagnostic and prognostic tools for acute GVHD. This review summarizes current information on the types of GVHD biomarkers, the omics tools used to identify them, the biomarkers currently validated as acute GVHD markers, and future recommendations for incorporating biomarkers into new grading algorithms for risk-stratifying patients and creating more personalized treatment courses. Future directions will include randomized evaluations of these biomarkers in multicenter prospective studies while extending on the need for biomarkers of chronic GVHD.

KW - Biomarkers

KW - Graft-versus-host disease (GVHD)

KW - Hematopoietic stem cell transplantation (HSCT)

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=84884673332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884673332&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1406-9

DO - 10.1007/s12185-013-1406-9

M3 - Article

C2 - 23959582

AN - SCOPUS:84884673332

VL - 98

SP - 275

EP - 292

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -